Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.

Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy

VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE

Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.

Here's How Provention's Treatment Works. Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
Provention

Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)

Teplizumab: Can We Delay the Onset of Type 1? Last updated: 6/7/21 By Dr. Francine...
@NCI

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Biotech Stock Review. Citius, CTXR

More Great News From Citius Pharma (CTXR).

UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
Internet Stock Review

Stocks On The Move!

Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...

Latest article

ARK VS. SARK | PAST STANCES

Long Ark Innovation 10/3/2022 | $37.90 #ARK, #ARKK, #SARK

ARK vs. SARK

Ever get really, really bearish and really, really wish you could find a simple way to make money in a bear market?

Adding ‘Internet of Things,’ Direct Communications (DCSX) $1.17 to the Watch List.

Chris Bursey, Member of Verizon's Internet of Things (IOT) Advisory Council, Charges Ahead as CEO of Direct Communication (DCSX).